For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
When we discuss innovation in clinical trials, it’s easy to think first of technologies involving digital health or evolving tools such as augmented intelligence. And these are certainly meaningful advancements.
But for every major improvement in our industry, there have been dozens of smaller innovations along the way. This incremental innovation, which results from the steady, focused efforts of sponsors and their partners, can create real value for biopharma companies.
One example of that value is the challenge of data standardization as a barrier breaker to enable transformative new technologies. These are technologies that can radically simplify or reimagine complex processes to dramatically reduce cycle timelines and variability across the clinical trial ecosystem.
Incremental innovation in action
Increasingly, global regulatory authorities are focusing on common standards for submissions. This includes most notably the FDA, which—since 2014— has specified formats for electronic submissions and can reject eCTD submissions for non-compliance.
Ideally, all trial data would be collected in a standardized format. But studies involve a massive and rapidly expanding volume of data, much of which is collected, unavoidably, in disparate legacy formats. Our industry is working toward uniformity, but in the interim sponsors need incremental ways to harmonize data, regardless of the source.
Recently, Parexel partnered with a large biopharma company to do just that. To enable interoperability and automation in our client’s data management processes, we helped implement CDISC standards for regulatory data submissions (SDTM) and analysis data (ADaM). First, we developed an ADaM Reviewer’s Guide template, based on CDISC/PhUSE guidance to comply with evolving regulatory requirements. With that standard in place, we then created SDTM mapping for our client’s Rave EDC platform. This mapping eliminated manual transformation and sped the delivery of data to analysis teams.
Making gains and moving forward
For this engagement, we focused on data transformation activities that include SDTM specification writing and SDTM dataset programming. Thanks to incremental change, we:
Since our initial project, we’ve expanded our work to include standards development for most of our client’s immuno-oncology development portfolio, which includes the organization’s highest priority assets. Our client has also asked us to create standards for electronic case report forms to accommodate legacy systems integrated into the existing R&D architecture.
Streamlining through partnership
When addressing the many challenges of clinical development, it can be helpful to have a partner in your corner. That’s one benefit of working with a CRO like Parexel. You get an expert and an ally who can offer new perspectives and expertise across the drug development process.
In the FSP model, we form a team matched to your organization’s specific needs. And that gives you the chance to innovate in ways that may not have been evident or possible before. When it comes to data standardization, for example, Parexel can create data standards that map to your internal systems and data lifecycle requirements, as we did for our client’s oncology portfolio.
What’s more, we can provide solutions that use our own systems and processes with your templates. When you opt to use a CRO’s systems, you benefit from your partner’s best practices, wide base of knowledge, and its own ongoing investment in innovation. At Parexel, we’re continually refining and streamlining our approach to data operations, which includes ongoing investment in developing comprehensive tools that eliminate and/or automate repetitive processes in the data lifecycle of a clinical trial:
Harness the power of incremental innovation
Today, sponsors are partnering more closely with CROs for data operations solutions and process improvement. It can be difficult to identify opportunities for optimizing data management across a complex data ecosystem, and even if you’ve targeted areas for improvement, implementing department- or enterprise-wide change can require significant effort. Does your organization have the resources, the right expertise, tools and enough flexibility to undertake these kinds of initiatives? Through an FSP collaboration, a CRO partner like Parexel can provide support — and tested technology solutions.
Interested in pursuing this kind of partnership? A few things to consider:
With continuous innovation, your savings and gains accrue over time. These gains are particularly valuable when it comes to data standards and process-intensive core functions of data management, biostatistics and statistical programming. Steady process improvement allows sponsors to reduce costs, shorten timelines, introduce labor-saving tools and help ensure higher quality data. Sponsors that invest in these improvements will be better positioned to take advantage of transformative technologies in the future.
An FSP partnership can be part of that investment. And the right partner will be committed to fostering efficiency — for you and for the patients you both serve.
Maximize the efficiency of regulatory operations with five key competencies
Jul 23, 2021
The upward trend of FSP outsourcing
Sep 29, 2022
3 steps for making your CRO relationships more successful
Jul 29, 2021
FSP 2.0: Why Talent Development is the New Talent Acquisition
Oct 26, 2022
Identifying the right FSP candidates on day one
Aug 9, 2021
Using ethical AI to streamline HEOR
Jan 26, 2024
Pharma Talk Radio: Building a Successful Relationship with your Development Partner
Oct 5, 2021
What's the Future of FSP?
Jan 6, 2022
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Clinical pharmacology, modeling and simulation to support FIH study design
Oct 21, 2021
Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data
Oct 15, 2021
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021